As December approaches, investors in Singular Genomics Systems might find themselves pondering whether it's time to reevaluate their stakes in this NASDAQ-listed company. With the stock's valuation market value sitting at $23M and an EPS estimate for the current year showing a loss of 34.8, there's a lot to consider. The health care equipment and supplies sector can be volatile, and Singular Genomics is no exception. The company's financials and market dynamics suggest a complex landscape, making it crucial for private investors to weigh their options carefully. Let's take a closer look at Singular Genomics Systems. Despite some challenges, we're optimistic about a potential recovery. Currently, the stock is priced at $23.00. Historically, it has shown a hype elasticity of 3.56, while competitors average around -0.15. We anticipate a price increase to $26.56 following the next press release. However, the stock's volatility is extremely high, making social media predictions less reliable. We expect a 15.48% price jump with the upcoming news, and the daily expected return is 2.87%. With a 90-day investment horizon, the next announcement is expected in about 8 days.
Singular Genomics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
Singular Genomics
financial leverage refers to using borrowed capital as a funding source to finance Singular Genomics Systems ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Singular Genomics financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Financial leverage can amplify the potential profits to Singular Genomics' owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its debt costs. The degree of Singular Genomics' financial leverage can be measured in several ways, including by ratios such as the debt-to-equity ratio (total debt / total equity), equity multiplier (total assets / total equity), or the debt ratio (total debt / total assets). Please check the
breakdown between Singular Genomics's total debt and its cash.
The company reported the previous year's revenue of 2.91
M. Net Loss for the year was (94.82
M) with loss before overhead, payroll, taxes, and interest of (24
K).
Current Deferred Revenue Breakdown
Singular Genomics' Current Deferred Revenue is increasing over the years with slightly volatile fluctuation. Current Deferred Revenue is expected to dwindle to about 4.5
M. Current Deferred Revenue usually refers to revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends. At present, Singular Genomics' Current Deferred Revenue is projected to increase significantly based on the last few years of reporting.
| 2010 | 1.59 Million |
| 2021 | 4.58 Million |
| 2023 | 6.08 Million |
| 2024 | 4.49 Million |
Timing can be everything in investing, and as December approaches, private investors in Singular Genomics Systems might find it prudent to reassess their positions. With a Price to Book ratio of just 0.24X, the stock may appear undervalued, suggesting potential for future growth. However, the company's high probability of bankruptcy at 96% and negative earnings per share estimates for both the current and next year highlight significant financial challenges. The firm's robust current ratio of 22.98X indicates strong liquidity, yet with a market capitalization of only 55.68 million, the road ahead could be bumpy. Investors should weigh these factors carefully, considering both the risks and opportunities before making any moves.
Our take on today Singular Genomics surge
Singular Genomics Systems has recently seen a significant uptick in its stock price volatility, with a standard deviation surpassing 17.47. This indicates that the market is reacting strongly to recent company news or developments. While such fluctuations can offer traders opportunities to profit from short-term price changes, they also highlight the need for careful analysis and risk management. Investors should stay informed about the factors driving this volatility to make informed decisions about their holdings in Singular Genomics.
The stock's above-average volatility suggests that understanding market trends can help investors better time their trades. During bear markets, increased volatility can impact Singular Genomics' stock price, prompting investors to adjust their portfolios by diversifying as prices decline.As we look towards December, Singular Genomics Systems presents an intriguing opportunity for investors willing to navigate its volatile landscape. With an analyst overall consensus of "Buy" and a possible upside price of
45.13, there's potential for significant gains. However, it's crucial to weigh this against the fiscal challenges, such as the EPS estimate for next year at -31.72, which indicates ongoing financial hurdles. Investors should carefully consider their risk tolerance and investment strategy before diving in, as the stock's journey could be as unpredictable as it is promising..
Vlad Skutelnik is a Macroaxis Contributor. Vlad covers stocks, funds, cryptocurrencies, and ETFs that are traded in North America, focusing primarily on fundamentals, valuation and market volatility. He has many years of experience in fintech, predictive investment analytics, and risk management.
View Profile This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Vlad Skutelnik do not own shares of Singular Genomics Systems. Please refer to our
Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to
editors@macroaxis.com